We propose a formal method to declare that findings from a primary study have been replicated in a follow-up study. Our proposal is appropriate for primary studies that involve large-scale searches for rare true positives (i.e. needles in a haystack). Our proposal assigns an r-value to each finding; this is the lowest false discovery rate at which the finding can be called replicated. Examples are given and software is available.
The use of big data is becoming a central way of discovering knowledge in modern science. Large amounts of potential findings are screened in order to discover the few real ones. In order to verify these discoveries a follow-up study is often conducted, wherein only the promising discoveries are followed-up. This is a common research strategy in genomics, proteomics and in other areas where high throughput methods are used. We show how to decide whether promising findings from the preliminary study are replicated by the follow-up study, keeping in mind that the preliminary study involved an extensive search for rare true signal in a vast amount of noise. The proposal computes a number, the r-value, to quantify the strength of replication.
We are concerned with situations in which many features are scanned for their statistical significance in a primary study. These features can be single nucleotide polymorphisms (SNPs) examined for associations with disease, genes examined for differential expression, pathways examined for enrichment, protein pairs examined for proteinprotein interactions, etc. Interesting features are selected for follow-up, and only the selected ones are tested in a follow-up study.
This approach addresses two goals. The first goal is to increase the number of cases in order to increase the power to detect a feature, at a lower cost. The second goal is to address the basic dogma of science that a finding is more convincingly a true finding if it is replicated in at least one more study. Replicability has been the cornerstone of science as we know it since the foundation of experimental science. Possibly the first documented example is the discovery of a phenomenon related to vacuum, made by Huygens in Amsterdam in the 17th century, who travelled to Boyle's laboratory in London in order to replicate the experiment and prove that the scientific phenomenon was not idiosynchronic to his specific laboratory with his specific equipment [1] . In modern research, the lack of replicability has deeply bothered behavioral scientists that compare the behavior of different strains of mice, e.g. in knockout experiments. It is well documented that in different laboratories, the comparison of behaviors of the same two strains may lead to opposite conclusions that are both statistically significant ( [2] , [3] , and Chapter 4 in [4] ). An explanation may be the different laboratory environment (i.e. personnel, equipment, measurement techniques) affecting differently the study strains (i.e. an interaction of strain with laboratory). This means that the null hypothesis that the effect is say non-positive is true in one laboratory, but false in the other laboratory, and thus the positive effect is not replicated in both laboratories. Replicability problems also emerge in medical research and are of great concern. Half of phase III clinical trials fail even though they rely on one of the many measures of success that were studied in the phase II trials ( [5] and [6] ). This suggests that the therapeutic effect discovered in the phase II study, which leads to the phase III study conducted in different patients, using similar but not identical methods and measures of success, was not replicated. Obviously the phase III studies were not under-powered, so failing to discover an effect suggests that the effect was absent from phase III even if it was present in phase II. In genomic research, the interest is in the genetic effect on phenotype. In different studies of the same associations with phenotype, we seem to be testing the same hypotheses but the hypotheses tested are actually much more particular. Whether a hypothesis is true may depend on the cohorts in the study, that are from specific populations exposed to specific environments (for particular examples, see section Results). However, if discoveries are made, it is of great interest to see whether these discoveries are replicated in different cohorts, from different populations, with different environmental exposures and different measurement techniques. The paramount importance of having replicated findings is well recognized in genomic research [7] . In particular, this is so in genome-wide association studies (GWAS), see [8] and [9] . As noted in [10] , the anticipated effects for common variants in GWAS are modest and very similar in magnitude to the subtle biases that may affect genetic association studies -most notably population stratification bias.
For this reason, they argue that it is important to observe the same association in other studies using similar, but not identical, sub-populations and methods. Obviously, splitting the data into two independent parts and doing the same analysis on each does not answer the above concerns.
Replicability problems arise in many additional scientific areas, and discussions of these problems reached prominent general-interest venues, for instance the New Yorker (December 13, 2010 ) and the Economist (October 19, 2013) . We need to have an objective way to declare that a certain study really replicates the findings in another study. This paper makes a concrete, objective, easy to apply, and rigorously motivated way to determine that a finding has been replicated.
Replicability versus meta-analysis. In many areas it is common to combine the results of studies that examine the same hypotheses by a meta-analysis. Pooling results across studies is especially attractive when single studies are underpowered, utilizing the potential increase in power of combining the studies, but the metaanalysis p-value tests only the null hypothesis of no signal in all studies. As a result, a strong signal in one of the studies (with p-value close to zero) is enough to declare the meta-analysis finding as highly significant.
A meta-analysis discovery based on a few studies is no better than a discovery from a single large study in assessing replicability, unless we are ready to assume that if a signal exists in one study it exists in all, i.e. that a discovery has to be a replicated discovery. This obviously need not be true, as discussed above. Similarly, replicability cannot be assessed in the following common practice: features are screened in a primary study, then the features with promising results are examined in a followup study, and the discoveries are only based on the results from the follow-up study. These are follow-up study discoveries, not discoveries that replicated from the primary study to the follow-up study.
In GWAS, a typical table of results reports the p-values in the primary and followup study, side by side, as well as the meta-analysis p-values, for the SNPs with the smallest meta-analysis p-values. Table 1 columns 1-6 is an example of such a table of results [11] . In replicability analysis, the null hypothesis of signal in at most one study is tested, the rejection of which yields the statistical significance of the replicability claim. (Replicability is sometimes referred to as reproducibility, but see [13] .)
The r-value for replicability. If a hypothesis in one study is rejected at the 0.05 level, and it is also rejected in the same direction in another study at the 0.05 level, then replicability is intuitively established. This is also a sound statistical claim, in the sense that the probability of claiming that a finding is replicated if the null hypothesis is true in at least one of the studies is at most 0.05. The need for a statistical framework for establishing replicability becomes essential with the use of high throughput methods. The potential to err in inference when more than one study is involved is more severe when each study is examining simultaneously many features. The choices for selection are much wider. Therefore, the statistical methods needed are more complicated than the very intuitive statistical method for establishing replicability when a single feature is involved.
Multiple testing methods are widely employed to adjust for the effect of selection, either by controlling the probability of erroneously selecting even a single feature (FWER), or by controlling the false discovery rate (FDR). The concern regarding the selected claims of replicability is even greater, because the selection takes place both after the primary study and after the follow-up study. Our method reports the r-value, that can be defined for either error rates for replicability analysis. Here we emphasize the FDR: Definition.The FDR r-value for feature i is the lowest FDR level at which we can say that the finding is among the replicated ones. The smaller the r-value, the stronger the evidence in favor of replicability of the finding. It can be compared to any desired level of FDR in the same way that a p-value is commonly compared to the desired false detection parameter α.
In this work we introduce a method for computing r-values for features examined in primary and follow-up studies. We suggest to complement tables of results that report for selected findings the primary, follow-up, and meta-analysis p-values, with an additional column of r-values. The r-values in column 7 of Table 1 are all below 0.05, concurring with the main replicability findings of [11] . The ranking of r-values is different than the ranking of the meta-analysis p-values, indicating the novelty of the added information. Table 2 shows the results of a somewhat more complicated example to be discussed below, where the difference between the meta-analysis and the replicability conclusions is more dramatic.
Assessing replicability from follow-up studies
We will concentrate on the widely used design in "omics" that examines m features in the primary study, and only a fraction thereof in the follow-up study. For other designs, see the Section on "Assessing replicability in other designs".
When m = 1, as we discussed in the introduction, replicability is established at the 0.05 significance level if both p-values are at most 0.05. When m > 1, this design can be analyzed by applying a multiple testing procedure on the maximum of the two studies p-values, setting conservatively the maximum value at one if the feature was not followed-up. This is not recommended since the price paid for multiplicity is too large. More powerful procedures for FWER and FDR control were suggested for this design in [16] , in which effectively the primary study p-values have to be adjusted for the multiplicity of m hypotheses, but the follow-up study p-values need to be adjusted only for the multiplicity of the hypotheses followed up. Here we suggest a generalization of the method of [16] , which offers further power gain in the typical situation in "omics" research where most of the hypotheses examined in the primary study are true null hypotheses. We demonstrate our proposal on p-values from GWAS. However, the p-values can obviously come from other applications such as exome-sequencing studies, ChIP experiments, or microarray studies.
Let f 00 denote the fraction of features, out of the m features examined in the primary study, that are null in both studies. We cannot estimate f 00 from the data, since only a handful of promising features (SNPs) are followed up in practice. However, f 00 is typically closer to one than to zero, and we can give a conservative guess for a lower bound on f 00 , call it l 00 . In typical GWAS on the whole genome, l 00 = 0.8 is conservative. We can exploit the fact that l 00 > 0 to gain power.
Computation of r-values for FDR-replicability

Data input:
(a) m, the number of features examined in the primary study.
(b) R 1 , the set of features selected for follow-up based on primary study results.
Let R 1 = |R 1 | be their number.
(c) {(p 1j , p 2j ) : j ∈ R 1 }, where p 1j and p 2j are, respectively, the primary and follow-up study p-values for feature j ∈ R 1 .
Parameters input:
(a) l 00 ∈ [0, 1), the lower bound on f 00 (see above), default value for whole genome GWAS is l 00 = 0.8.
(b) c 2 ∈ (0, 1), the emphasis given to the follow-up study (see Section Variations), default value is c 2 = 0.5.
Definition of the functions
(b) For every feature j ∈ R 1 compute the following e-values
, where rank(e j ) is the rank of the evalue for feature j ∈ R 1 (with maximum rank for ties).
4. The FDR r-value for feature i ∈ R 1 is the solution to f i (r i ) = r i if a solution exists in (0, 1), and 1 otherwise. The solution is unique, see SI Lemma S1.1 for a proof.
The r-values can be computed using our web application http://www.math.tau.ac.il/$\sim$ruhelle An R script is also available in RunMyCode,http://www.runmycode.org/companion/view/542. For l 00 = 0, declaring as replicated the findings with r-values at most q coincides with Procedure 3.2 in [16] . It is easy to see that with l 00 > 0, we will have at least as many replicability claims as with Procedure 3.2 in [16] . Next we show in GWAS examples and simulations that the power increases with l 00 , and can lead to many more discoveries than with Procedure 3.2 in [16] , while maintaining FDR control.
Results
We consider three recent articles reporting GWAS, where hundreds of thousands of SNPs are examined in the primary studies, and only a small fraction of these SNPs are examined in the follow-up studies. In these examples, the primary and follow-up studies differ in the sub-populations examined, and may also differ in design and analysis. In addition, the primary and follow-up studies may differ in quality. It is therefore of scientific importance to discover which associations were replicated. The examples differ in design, and in the selection rules for forwarding SNPs for follow-up. In the first example, there is one primary study and one follow-up study, few dozen SNPs are followed up, and only a handful have r-values below 0.05. In the second example, the primary study is a meta-analysis of three studies, more than a hundred hypotheses are followed-up, and few dozen SNPs have r-values below 0.05. In the third example, there were three stages: a primary study, then a follow-up study, and then an additional follow-up study that was based on the first follow-up study.
Our first example is GWAS of IgA nephropathy in Han Chinese [11] . To discover association between SNPs and IgA nephropathy, 444882 SNPs were genotyped in 1523 cases from southern China, and 4276 controls from Singapore and from southern and northern China, with the same ancestral origin. For follow-up, 61 SNPs were measured in two studies: 1402 cases and 1716 controls from northern China, and 1301 cases and 1748 controls from southern China. The 61 SNPs selected for followup had primary study p-values below 10 −5 . Table 1 shows the seven SNPs with the smallest meta-analysis p-values, out of the 61 SNPs followed up. The associations for these seven SNPs have been replicated with r-values ≤ 0.05 for l 00 = 0.8. The seven SNPs clearly stand out from the remaining 54 SNPs followed-up, that have r-values of one, see Table S1 in the Supporting Information (SI). If the researcher is willing to assume only a lower bound of 0.5 or of zero for f 00 , then the r-values are larger than with l 00 = 0.8. Table S1 in the SI shows that with l 00 = 0.5 and l 00 = 0, respectively, only six and five SNPs had r-values below 0.05.
Our second example is GWAS of Crohn's disease (CD). To discover associations between SNPs and CD, [17] examined 635547 SNPs on 3230 cases and 4829 controls of European descent, collected in three separate studies: NIDDK4, WTCCC5, and a Belgian-French study. For follow-up, 126 SNPs were measured in 2325 additional cases and 1809 controls as well as in an independent family-based dataset of 1339 trios of parents and their affected offspring. The two smallest p-values in each distinct region with primary study p-values below 5 × 10 −5 were considered for follow-up. Table S2 in the SI shows the 126 SNPs followed-up. Applying our proposal with parameter l 00 = 0.8, we decide that 52 SNPs have replicated associations at r-values ≤ 0.05. The 52 SNPs with replicated associations did not correspond to the 52 SNPs with the smallest meta-analysis p-values. For example, the SNP in row 35 had the 35th smallest meta-analysis p-value, but its r-value was 0.09, thus it was not among the 52 replicated discoveries.The last column of Table S2 in the SI marks the 30 SNPs that were highlighted as "convincingly (Bonferroni P < 0.05) replicated CD risk loci", based on the follow-up study p-values, in Table 1 of the main manuscript of [17] . These 30 SNPs have r-values below 0.05, so they are a subset of the 52 replicated discoveries. Our replicability analysis discovers more loci, in particular three loci (rows 34, 44, and 59 in Table S2 of the SI) that did not reach the conservative Bonferroni threshold of [17] on the follow-up study p-values, yet were pointed out in Table 2 of [17] to be "Nominally (uncorrected P < 0.05) replicated CD risk loci".
Our third example is GWAS of type 2 diabetes (T2D). To discover association between SNPs and T2D, [18] examined more than two million SNPs imputed from about 400000 SNPs collected on 4549 cases and 5579 controls combined from three separate studies: DGI, WTCCC, and FUSION. For follow-up, 68 SNPs were measured in 10037 cases and 12389 controls combined from additional genotyping of DGI, WTCCC, and FUSION. The 68 SNPs chosen for follow-up had primary study p-values below 10 −4 , and they were in loci that were not discovered in previous studies. For additional follow-up, 11 out of the 68 SNPs were measured in 14157 cases and 43209 controls of European descent combined from 10 centers. The 11 SNPs forwarded for an additional follow-up had p-values below 0.005 in the first follow-up study, as well as meta-analysis p-values below 10 −5 when combining the evidence from the primary study and the first follow-up study. While there was no evidence of replicability from the primary study to the follow-up studies, there was evidence of replicability from the first followup study to the second follow-up study. Table 2 shows the 11 SNPs followed-up from the first follow-up study to the second follow-up study. Applying our proposal with l 00 = 0, we decide that five SNPs have replicated associations with r-values ≤ 0.05. Note that we set l 00 = 0 since most of the 68 SNPs in the first follow-up study are already believed to be associated with the disease.
Derivation and properties
Here we give the formal framework for replicability analysis, and the theoretical properties of our proposal. The family of m features examined in the primary study, indexed by I = {1, . . . , m}, may be divided into four sub-families with the following indices: I 00 , I 01 , I 10 , and I 11 , for the features with hypotheses that are, respectively, null in both studies, null in the primary study only, null in the follow-up study only, and non-null in both studies. Suppose R replicability claims are made by an analysis. Denoting by R ij the number of replicability claims from sub-family I ij , R 11 is the number of true replicability claims, and R − R 11 = R 00 + R 01 + R 10 is the number of false replicability claims.
The FDR for replicability analysis is the expected proportion of false replicability claims among all those called replicated: 
Arbitrary dependence among the p-values within the primary study, when in
Step 3 m is replaced by m
Arbitrary dependence among the p-values within the primary study, and the selection rule is such that the primary study p-values of the features that are selected for follow-up are at most a fixed threshold t ∈ (0, 1), when c 1 computed in Step 3(a) is replaced bỹ
where
. Steps 3(b) and 3(c) remain unchanged. In step 4, the FDR r-value for feature i ∈ R 1 is r i = min{x : f i (x) ≤ x} if a solution exists in (0, 1), and one otherwise.
See the SI for a proof. The implication of item 3 is that for FDR-replicability at level q, if t ≤ c 1 (q)q/m, no modification is required, so the procedure that declares as replicated all features with r-values at most q controls the FDR at level q on replicability claims for any type of dependency in the primary study. Note that the modification in item 3 will lead to more discoveries than the modification in item 2 only if t <
In the SI we show realistic GWAS simulations that preserve the dependency across pvalues in each study. For l 00 ∈ {0, 0.8, 0.9, 0.95, 0.99}, the FDR of the procedure that declares findings with r-values (computed in Steps 1-4 of the original proposal) at most 0.05 as replicated is controlled below level 0.05, suggesting that this procedure is valid for the type of dependency that occurs in GWAS. Since this procedure can be viewed as a two dimensional variant of the BH procedure, and the BH procedure is known to be robust to many types of dependencies, we conjecture that for l 00 ≤ f 00 , our procedure controls the FDR at the nominal level q for most types of dependencies that occur in practice, even if hypotheses with primary study p-values above c 1 (q)q/m are followed-up. In Table S5 of the SI we further show the superior power of our procedure over applying the BH procedure on the maximum of the two studies pvalues (at level 0.05/(1 − l 00 ), where the maximum value is set to one for j / ∈ R 1 ).
Variations
Choice of emphasis between the studies
The e-value computation requires combining the p-values from the primary and the follow-up study using a parameter c 2 , which we set to be c 2 = 0.5 in the computation above. More generally, for FDR control we need to first select c 2 ∈ (0, 1). We shall show the effect the choice of c 2 has on the r-values for given p-values, and argue from power considerations that the choice c 2 = 0.5 is reasonable.
The following procedure is identical to that of declaring the set of findings with rvalues at most q as replicated, see proof in SI Lemma S1.1. First, compute the number 9 of replicability claims at level q as follows:
Next, declare as replicated findings the set
From this equivalent procedure it is clear that a larger choice c 2 ∈ (0, 1) will make the threshold that p 2j has to pass larger, but the threshold that p 1j has to pass smaller, so for the extreme choice c 2 ≈ 1, the discovered findings can only be features with tiny primary study p-values, and for the extreme choice of c 2 ≈ 0, the discovered findings can only be features with tiny follow-up study p-values. For q small, the primary and follow-up study p-values will have the same threshold if
, which is close to zero if R 1 /m is very small (as is typical in GWAS). Therefore, this choice is not recommended unless the power of the followup study is extremely large. For the choice c 2 = 0.5, the threshold for the follow-up study p-value is larger than for the primary study p-value by the factor m(1 −l 00 )/R 1 , i.e. the ratio of the number of hypotheses that should be adjusted for in the primary study to that in the follow-up study. We show next that this choice is good from efficiency considerations.
In simulations, detailed in the SI, we observed that for a given l 00 the optimal c 2 , i.e. the choice of c 2 that maximizes power, has only a small gain in power over the choice c 2 = 0.5. We considered m = 1000 SNPs, out of which f 00 = 0.9 had no signal, f 01 = 0.025 had signal only in the follow-up study, f 10 = 0.025 had signal only in the primary study, and f 11 = 0.05 had signal in both studies. The power to detect the signal in the primary study was set to be π 1 = 0.1 for a threshold of 0.05/m, and the power to detect the signal in the follow-up study was set to be π 2 ∈ {0.8, 0.5, 0.2} for a threshold of 0.05/R 1 . The selection rule for follow-up was the BH procedure at level c 1 (q)q on the primary study p-values, with q = 0.05. See Section S3 in the SI for a discussion of the advantage of this selection rule over other selection rules.
The power increased with l 00 as well as with π 2 . In the SI, Table S4 shows that the gain in power of using l 00 > 0 over l 00 = 0 can be large. Figure S1 shows the average power and the power for at least one true replicability discovery as a function of c 2 .
Our simulations mimic the typical setting in GWAS on the whole genome, where SNPs that are associated with the phenotype have typically low power (0.1 in the above simulations) to pass the severe Bonferroni threshold of the large number of hypotheses examined in the primary study, yet the power to pass the far less severe Bonferroni threshold of the few dozen hypotheses examined in the follow-up study is greater (0.2, 0.5, or 0.8 in the above simulations). Therefore, for GWAS on the whole genome, we recommend setting c 2 = 0.5.
FWER-replicability
The FWER criterion, F W ER = Pr(R 00 + R 01 + R 10 > 0), is more stringent than the FDR, yet it may sometimes be desired. We define the FWER r-value as the lowest FWER level at which we can say that the finding has been significantly replicated. The r-value can be compared to any desired level of FWER. An FWER controlling procedure for replicability analysis was suggested in [16] : it applies an FWER controlling procedure at level c 1 α on the primary study p-values, and at level c 2 α on the subset of discoveries from the primary study that were followed-up, where c 1 + c 2 = 1. If a non-zero lower bound on f 00 is available, then this lower bound can be used in order to choose parameters (c 1 , c 2 ) with a sum greater than one. Specifically, for FWER control using Bonferroni, the data input and parameters input is the same as in our proposal for FDR-replicability in Steps 1 and 2, but the computation in Step 3 is different. For feature j ∈ R 1 ,
.
The Bonferroni r-value for feature j is the solution to f We computed the Bonferroni r-values in a GWAS of thyrotoxic periodic paralysis (TPP) [19] . In 70 cases and 800 controls from the Hong Kong (Southern) Chinese population, 486782 SNPs were genotyped. Table S3 shows the four most significant SNPs followed-up in additional 54 southern Chinese TPP cases and 400 healthy Taiwanese controls. The associations were successfully replicated with Bonferroni rvalues far below 0.05, concurring with the claim in [19] that "Associations for all four SNPs were successfully replicated".
Assessing replicability in other designs
The concept of the r-value is also relevant to the communication of the results of replicability in other designs. If n > 2 studies examine a single feature, then replicability of the finding in all n studies is established at the 0.05 significance level if the maximum p-value is at most 0.05. However, if a weaker notion of replicability is of interest, e.g. that the finding has been replicated in at least two studies, then the evidence towards replicability can be computed as follows. First, for every subset of n − 1 studies, a meta-analysis p-value is computed. Then, replicability in at least two studies is established at the 0.05 significance level if the maximum of the n meta-analysis p-values is at most 0.05. This can be generalized to discover whether the finding has been replicated in at least u studies, where u ∈ {2, . . . , n}, as detailed in [20] .
If n ≥ 2 studies examine each m > 1 features, then for each i ∈ {1, . . . , m} the p-value for testing for replicability can be computed as above, but instead of comparing each to 0.05, the BH procedure is applied and the discoveries are considered as replicated findings. The procedure was suggested in [21] , and for n = 2 it amounts to using the maximum of the two studies p-values for each feature in the BH procedure. The power of this procedure may be low when a large fraction of the null hypotheses are true, since the null hypothesis for replicability analysis is not simple, and the BH procedure is applied on a set of p-values that may have a null distribution that is stochastically much larger than uniform. The loss of power of multiple testing procedures can indeed be severe when using over-conservative p-values from composite null hypotheses [22] . An empirical Bayes approach for discovering whether results have been replicated across studies was suggested in [23] , and compared with the analysis of [21] , concluding that the empirical Bayes analysis discovers many more replicated findings. The accuracy of the empirical Bayes analysis relies on the ability to estimate well the unknown parameters, and thus it is suitable in problems such as GWAS, where each study contains hundreds of thousands of SNPs, and the dependency across SNPs is local, but may not be suitable for applications with a smaller number of features and non-local dependency. A method based on relative ranking of the p-values to control their "irreproducible discovery rate" was suggested in [24] . A list-intersection test to compare top ranked gene lists from multiple studies to discover the common significant set of genes was suggested in [25] .
To summarize, although for m = 1 there is a straightforward solution for the problem of establishing replicability, once we move away from this simple setting the problem is more complicated. For designs with more than one potential finding, it is very useful to quantify and report the evidence towards replicability by an r-value. The r-value is a general concept, but the r-value computation depends on the multiple testing procedure used, which in turn depends on the design of the replicability problem.
Discussion
The r-value was coined in the FDR context, in accordance with the commonly used q-value [26] . We proposed the r-value as an FDR-based measure of significance for replicability analysis. We showed in GWAS examples that the smallest meta-analysis p-values may not have the strongest evidence towards replicability of association, and we suggest to report the r-values in addition to the meta-analysis p-values in the table of results.
In practice, the primary study p-values are rarely independent. We prove that our main proposal controls the FDR on replicability claims if the primary study p-values are independent, and suggest modifications of the proposal that are more conservative but have the theoretical guarantee of FDR control for any type of dependency among the primary study p-values. From empirical investigations, we conjecture that the conservative modifications in items 2 and 3 of Theorem 1 are unnecessary for the types of dependencies encountered in GWAS. For our second example, of GWAS in CD, applying the more conservative proposal in item 2 of Theorem 1 resulted in 34 discoveries. In future research we plan to investigate theoretically the effects of local dependency and positive dependency in the primary study.
We saw examples where the primary study was comprised of more than one study, and more than one follow-up study was performed. In the current work, we used all the information from the primary studies for selection for follow-up, and to establish replicability the meta-analysis p-values of the primary studies and the meta-analysis pvalues of the follow-up studies were used. Alternative ways of combining the evidence, that can also point to the pair of studies in which the evidence of replication is strongest, will be considered in the future. The scientific evidence of two out of two (2/2) studies is more convincing than that of two out of three (2/3) studies or two out of n (2/n) studies, and the scientific evidence of 3/n studies is more convincing than that of 2/n towards replicability. In the future, we plan to develop methods for computing the r u/n -value, that quantifies the evidence that the finding has been replicated in at least u out of n studies, for 2 ≤ u ≤ n. This problem has been addressed in [20] , but as was shown in [16] alternatives along the lines of the procedures suggested here may benefit from increased power.
A referee pointed out that follow-up studies may be designed to give more trustworthy data, using more expensive equipment, e.g. using PCR or fine linkage analysis. If the aim is to detect associations in the follow-up study, then there is no need to combine the evidence from the primary study with that of the follow-up study. However, if the aim is to detect replicated associations, then it may be of interest to have unequal penalties for the error of discovering a finding that is only true in the primary study, and the error of discovering a finding that is only true in the follow-up study. Developing procedures that give unequal penalties to these two errors is a challenging and interesting problem for future research, which may be approached by utilizing weights [27] . Table 1 : Replicability analysis for FDR control for the study of [11] : GWAS of IgA nephropathy in Han Chinese. The number of SNPs in the primary study was 444882, and 61 were followed-up. For the seven most significant meta-analysis p-values: the position (columns 1-3), the primary and follow-up study p-values (column 4 and 5), the meta-analysis p-values (column 6), and the r-values (column 7). See Table S1 of Table 2 : Replicability analysis for FDR control for the study of [18] on GWAS of T2D. The number of SNPs in the first follow-up study was 68, and 11 were followedup to the second follow-up study. For these 11 SNPs: the positions (columns 1-2), the primary study p-values and first and second follow-up studies p-values (columns 3-5), the meta-analysis p-values from all 3 studies (column 6), and the r-values quantifying the evidence of replicability from the first to the second follow-up study (column 7). The lower bound for f 00 was l 00 = 0 for the r-value computation, since the set of SNPs in the first follow-up study are already believed to be associated with T2D. 
A Proof of Theorem 1
The procedure that declares as replicated all features with r-values ≤ q is equivalent to the procedure in Section Variations, where the choice of emphasis between the studies is discussed (bottom of page 4), as proved in Lemma A.1. We shall show that our proposal, in its most general form (i.e. with c 2 ∈ (0, 1)), controls the FDR at level at most
under the conditions of Theorem 1, where f 0j = |I 0j | m , j ∈ {0, 1}, and f 10 =
Before proving the above upper bound on FDR, we shall show that if the above upper bound holds and l 00 ≤ f 00 , Theorem 1 follows. Note that if the constants (l 00 , c 2 ) satisfy the inequality f 00 c 1 (q)c 2 q + f 01 c 1 (q) + c 2 ≤ 1, then the FDR for replicability analysis is controlled at level at most q. This inequality holds for any choice of (l 00 , c 2 ) that satisfies the relationship
Unfortunately, f 00 and f 01 are not known. If the guess for l 00 is indeed conservative, i.e. l 00 ≤ f 00 , then the above inequality holds since f 00 ≤ 1 − f 01 . Thus, for any value l 00 ≤ f 00 and c 2 ∈ (0, 1), the FDR for replicability analysis is controlled at level at most q.
Proof for the upper bound in (1). Let R j be the indicator of whether j was declared replicated for j = 1, . . . , m, and R = m j=1 R j . The FDR for replicability analysis is
For items 1-3 we shall find an upper bound for each of the terms, specifically we shall show the following inequalities (3)-(5).
Obviously the upper bounds in (3)-(5) and the equality in (2) complete the proof for the upper bound in (1). The upper bounds in (3) and (4) follow directly from [16] . The key difference from [16] is the fact that we consider a tighter upper bound for E j∈I 00 R j / max(R, 1) given in (5). We shall proceed to prove inequality (5) for items 1-3.
We shall start with the proof of item 1 for the case where the p-values within the follow-up study are jointly independent. Inequality (3) follows from the derivations leading to (A.3) in [16] 1 . Inequality (4) follows from the derivations leading to (A.7) in [16] , and by taking the expectation of the expression in (A.7) over the primary study p-values. We shall now prove inequality (5). We recall the following definitions from [16] . Let P (j) 1 and P (j) 2 denote the vectors P 1 = (P 11 , . . . , P 1m ) and P 2 = (P 21 , . . . , P 2m ) with, respectively, P 1j and P 2j excluded. For j ∈ {1, . . . , m} arbitrary fixed, let R (j) 1 (P (j) 1 ) ⊆ {1, . . . , j − 1, j + 1, . . . , m} be the subset of indices selected along with index j. Note that since the selection rule is stable, this subset is fixed as long as P 1j is such that j is selected based on (P (j) 1 , P 1j ). For any j ∈ {1, . . . , m} and given
Let e r as the event in which if j ∈ I 00 ∪ I 01 ∪ I 10 is declared replicated, r hypotheses are declared replicated including j, which amounts to:
2 ) : e r is the entire space of (P Note that from the equivalent procedure in Section Variations the following equality 1 Replacing q 1 with c 1 q, q − q 1 with c 2 q, and |I 0 | with |I 01 | in the derivations leading to (A.3) in [16] we obtain the proof of inequality (3). This replacement should be made in all the derivations in [16] used in this proof.
2 The e-values are closely related to T -values defined in Appendix A of [16] . Specifically, e (j) i = T i q/m for j ∈ {1, . . . , m} and i ∈ {1, . . . , j − 1, j + 1, . . . , m}.
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follows.
where the inequality in (6) follows from the fact that for any given realization of |R 1 | and value of r such that r > |R 1 |, C (j) r = ∅, the inequality in (7) follows from the independence of the p-values and the fact that P 1j and P 2j are null-hypothesis p-values, and the first equality in (7) follows from the fact that We shall now prove item 1 for the case where the p-values within the follow-up study have property PRDS. The inequalities (3) and (4) for this case follow from the results in the Supplementary Material of [16] . Specifically, inequality (3) follows from the proof of Theorem S3.1 in [16] and inequality (4) follows from the proof of item 2 in Lemma S2.1 in [16] . For j ∈ I 00 and an arbitrary fixed p 1 = (p 11 , . . . , p 1m ) such that
where inequality (8) follows from the independence of the p-values across the studies and the fact that P 2j is a null-hypothesis p-value. We shall now show that inequality (9) holds. It follows from item 1 of Lemma S2.1 in the Supplementary Material of [16] that
for any p 1 = (p 11 , . . . , p 1m ) and j ∈ I 10 ∩ R 1 (p 1 ). It is straightforward to verify that this result holds for j ∈ I 00 ∩ R 1 (p 1 ) as well, yielding inequality (9) . It follows that for j ∈ I 00 ,
Note that for j ∈ I 00
The inequality in (13) follows from the independence of the p-values within the primary study and the fact that P 1j is a null-hypothesis p-value. The equality in (13) follows from the fact that ∪ 1 , represented as a union of disjoint events. Combining (10) with (13) we obtain for j ∈ I 00
Summing this upper bound over all j ∈ I 00 we obtain the upper bound in (5), thus completing the proof of item 1 for the case where the set of p-values within the follow-up study has property PRDS.
We shall now prove item 2. Inequalities (3) and (4) follow from the results in the Supplementary Material of [16] . Specifically, inequality (3) follows from the derivations leading to (S2.8) and inequality (4) follows from the proof of item 2 and item 3 of Lemma S2.1 in [16] . We shall now prove inequality (5) . Both for the case where the p-values within the follow-up study are independent and for the case where the p-values within the follow-up study have property PRDS, the derivations leading to (10) and (12) remain valid when m is replaced with m * in those derivations and in the terms defining C (j) r . Therefore
It follows from the derivations leading from (S2.3) to (S2.8) in the Supplementary Material of [16] , replacing I 0 with I 00 , q 1 with c 1 (q)q, and the event C 
Combining (10) with m replaced by m * , (15) and (16) we obtain inequality (5), which completes the proof of item 2.
We shall now prove item 3. If we replace q 1 with c 1 (q)q and |I 0 | with |I 01 | in the derivations leading to (S2.18) in the Supplementary Material in [16] , we obtain
It follows from the definition of c 1 (x) that c 1 (x) ≤ c 1 (x) for all x ∈ (0, 1), in particular c 1 (q) ≤ c 1 (q). Inequality (3) follows immediately from this inequality and inequality (17) . Inequality (4) is obtained using the derivations from the main manuscript and the Supplementary Material of [16] , as detailed in the proof of inequality (4) in item 1. For this item q 1 is replaced with c 1 (q)q in those derivations, and in order to obtain inequality (4) we use the fact that c 1 (q) ≤ c 1 (q). We shall now prove inequality (5) . Both for the case where the p-values within the follow-up study are independent and for the case where the p-values within the follow-up study have property PRDS, the derivations leading to (10) and (11) remain valid when c 1 (q) is replaced with c 1 (q) in those derivations and in the terms defining C (j) r . Therefore
It follows from the derivations leading from (S2.9) to (S2.18) in the Supplementary Material of [16] , replacing I 0 with I 00 , q 1 with c 1 (q)q, and the event C 
Combining (18) with (19), and using the fact that c 1 (q) ≤ c 1 (q), we obtain inequality (5), which completes the proof of item 3.
Lemma A. 
Declaring the features with r-values at most q is equivalent to the procedure given in Section Variations (left column at the bottom of page 4).
For r-values computed with the modification in item 2 of Theorem 1, declaring the features with r-values at most q is equivalent to the procedure given in Section
Variations where m is replaced by m
The function c 1 (x) in item 3 of Theorem 1 is well-defined. For r-values computed with the modification in item 3 of Theorem 1, declaring the features with
r-values at most q is equivalent to the procedure given in Section Variations where c 1 (q) is replaced byc 1 (q).
Proof of Lemma A.1.
Proof of items 1 and 2 of Lemma A.1. Simple calculations show that g(x) = xc 1 (x) is a strictly increasing function of x for x > 0. Therefore for each feature j ∈ R 1 , e j (x)/x is a strictly decreasing function of x. Despite the fact that e j (x)/[x · rank(e j (x))] may not be monotone decreasing functions for j ∈ R 1 , it is guaranteed that f i (x)/x = min {j:e j (x)≥e i (x),j∈R 1 } e j (x)/[x · rank(e j (x))] is a strictly decreasing function of x for each feature i ∈ R 1 . 3 Therefore if there exists a solution r i ∈ (0, 1) to f i (x)/x = 1, then it is unique, since for all x < r i , f i (x)/x > 1 and for all x > r i , f i (x)/x < 1. When the function f i (x) is computed with the modification in item 2 of Theorem 1, the proof remains the same, since m * does not depend on x.
Proof of items 3-5 of Lemma A.1. It is easy to see that for the procedure given in Section Variations, R 2 = {i ∈ R 1 : f i (q) ≤ q}. The same result holds for the function f i (x) with the modification of item 2 and item 3 of Theorem 1 and the modified procedures in items 4 and 5 of Lemma A.1, respectively. Therefore it is enough to prove that for i ∈ R 1 , f i (q) ≤ q if and only if r i ≤ q for each one of the items of Lemma A. 
Proof of item 4. We need to prove that when we replace m with m * = m m i=1 1/i in the computation of f i (x) and r i for i ∈ R 1 , r i ≤ q if and only if feature i is rejected by the procedure in Section Variations, where m is replaced by m = m * . It is easy to see that for this modified procedure, R 2 = {i ∈ R 1 : f i (q) ≤ q}, where f i (q) is computed with the modification above. It remains to prove that {i ∈ R 1 : f i (q) ≤ q} = {i ∈ R 1 : r i ≤ q}. Since f i (x) is continuous, it is obvious that the modified function f i (x) is continuous as well. Moreover, f i (x)/x is monotone decreasing in x, thus using arguments similar to the proof of item 3 the result follows. Proof of item 5. The proof that the function c 1 (x) is well-defined, i.e. that for all x ∈ (0, 1) there exists a solution a to a ⌈tm/(ax)−1⌉ i=1 1/i = c 1 (x) is technical and therefore is omitted. Similarly to the items above, we need to prove that {i ∈ R 1 : f i (q) ≤ q} = {i ∈ R 1 : r i ≤ q}, where f i (x) and r i are the modified functions and r-values respectively, given in item 3 of Theorem 1. We shall first show that if f i (q) ≤ q, then there exists r i = min{x : f i (x) ≤ x} ∈ (0, 1). It can be shown that c 1 (x) is right continuous, 5 and thereforef i (x) is right continuous. If f i (q) ≤ q, then inf{x :f i (x) ≤ x} < 1. It remains to show that inf{x :f i (x) ≤ x} = 0, sincef i (x) is right continuous for all x ∈ (0, 1), therefore if inf{x :
We shall now prove that inf{x :f i (x) ≤ x} = 0. Note that c 1 (x) ≤ c 1 (x) for all x ∈ (0, 1), therefore it can be shown thatf i (x) ≥ f i (x) for all x ∈ (0, 1). As we noticed in the proof of item 3 of Lemma A.1, f i (x) can be defined for x ∈ [0, 1), 4 It is easy to see that f i (x) is continuous at each x 0 where e-values are unique. Note that for each j ∈ R 1 the numerator of e j (x)m/rank(e j (x)) is continuous and there is a small neighbourhood of x 0 where rank(e j (x)) does not change, yielding that e j (x)m/rank(e j (x)) is continuous at x 0 . Since the minimum of continuous functions is also continuous, f i (x) is a continuous function as well. For x 0 where e-values are not unique, the proof is more involved. In these points the functions e j (x)m/rank(e j (x)) may be not continuous, however f i (x) is continuous. 5 The proof that c 1 (x) is right continuous is based on the facts that ⌈tm/(ax) − 1⌉ is a right continuous function of x and c 1 (x) is a continuous function. Since the proof is technical, it is omitted.
it is a continuous function on [0, 1), and f i (0) > 0. Therefore there exists δ > 0 such that f i (x) > x for x ∈ [0, δ). It follows thatf i (x) > x for x ∈ (0, δ), therefore inf{x :f i (x) ≤ x} = 0. Thus we have proved that if f i (q) ≤ q, then there exists r i = min{x : f i (x) ≤ x} ∈ (0, 1). From the definition of r i we obtain r i ≤ q. Assume now that r i ≤ q, i.e. min{x : f i (x) ≤ x} ≤ q. It can be shown that f i (x)/x is a monotone decreasing function,
B GWAS Real data examples
Tables S1, S2, and S3 show the results of the replicability analysis for the SNPs followed-up based on the results of the primary study (or studies). Columns 1-3 in Tables S1 and S2 and columns 1-2 in Table S3 contain the position of each SNP. Columns 4-5 in Tables S1 and S2 and columns 3-4 in Table S3 show the primary and follow-up p-values. Columns 6-8 in Tables S1 and S2 and column 6 in Table  S3show the r-values for different choices of l 00 . Column 9 in Tables S1 and S2 and column 5 in Table S3 shows the meta-analysis p-values, which are the unadjusted p-values computed using the data from the primary and follow-up studies for testing the global null hypothesis of no association in any of the studies. In Tables S1 and S2 the rows are sorted by the meta-analysis p-values, and the handful of findings with most significant meta-analysis p-values which were reported as interesting in the published works are marked with an * in the last column. Table S2 : Replicability analysis for the study of [17] , with 635547 SNPs in the primary study, and with 126 SNPs followed-up. The last column marks the 30 SNPs that were highlighted as "convincingly (Bonferroni P < 0.05) replicated CD risk loci", based on the follow-up study p-values, in Table 2 of the main manuscript of [17] . Table S3 : Replicability analysis for FWER control for the study of [19] on GWAS of TPP. The number of SNPs in the primary study was 486782, and four SNPs were followed-up. The lower bound for f 00 was l 00 = 0.8 for the r-value computation.
Chr. 
C Choice of selection rule for replicability analysis
Although any stable selection rule can be used, some selection rules may be more efficient than others. For a given FDR level q, the promising hypotheses for replicability analysis are the set of hypotheses rejected with the BH procedure at level c 1 (q)q on the primary study p-values. Therefore, for the purpose of replicability analysis, the set of hypotheses to be considered should be only this set or a subset thereof. This means that if R 1 hypotheses are followed-up, not all R 1 features need to be selected for a replicability analysis at a predetermined level q. The advantage of selecting only the relevant subset is that the power of the procedure will be greater since the problem of multiplicity among the selected will be smaller, without compromising any potential replicability claims. Specifically, in order for the r-value to be below q, only the subset of R 1 hypotheses selected for follow-up with primary study p-values that are small enough need to be considered, where our requirement for small enough is as follows: when applying the BH procedure at level c 1 (q)q on p 11 , . . . , p 1m , these hypotheses will be among the rejected. Computing the r-values for the subset of R 1 with small enough primary study p-values, we receive smaller r-values than if all R 1 SNPs are considered for replicability analysis.
For the example of GWAS of IgA nephropathy, for an FDR level of 0.05, only 14 SNPs out of the 61 followed-up had primary study p-values small enough to be considered for replicability analysis. The number of r-values below 0.05 was still seven with this modified selection rule, but these seven r-values were smaller than the r-values for the seven SNPs in We conducted simulations in order to investigate how the power and FDR of our proposal depends on c 2 ∈ (0, 1) and l 00 ∈ {0, 0.5, 0.8, 0.9} for q = 0.05. The p-values were generated independently as follows. Let P 1j and P 2j be the p-values in the primary and in the follow-up study, respectively, for feature j. We set P 1j = 1−Φ(X 1j ) and P 2j = 1 − Φ(X 2j ), where X 1j ∼ N(µ 1j , 1), X 2j ∼ N(µ 2j , 1). For i ∈ {1, 2}, we set µ ij = 0 if feature j comes from a true null hypothesis in study i, and µ ij = µ i > 0 if feature j comes from a false null hypothesis in study i. The values of µ 1 and µ 2 were set according to the requirement that the power of the Bonferroni procedure at level 0.05 in the primary study is π 1 , and in the follow-up study is π 2 , for π 1 = 0.1 and π 2 ∈ {0.2, 0.5, 0.8}. Specifically, we set
, where Φ −1 is the inverse of the cumulative distribution function of a standard normal variable and R 1 is the number of rejected hypotheses by the BH procedure at level c 1 × 0.05 applied on the primary study p-values. In addition, m = 1000, f 00 = 0.9, f 01 = f 10 = 0.025, f 11 = 0.05.
The simulation results were based on 10000 repetitions. The FDR was estimated by averaging the false discovery proportion. The average power was estimated by the average number of true replicability claims, divided by mf 11 . We also estimated the probability that our proposal makes at least one true replicability claim (which we refer to as "power for at least one") by the proportion of repetitions in which at least one true replicability claim was made. The standard errors of the estimators were of the order of 10 −3 or 10 −4 for all the sets of parameters.
A comparison of columns 8-9 with columns 3, 5, and 7 in Table S4 shows that the gain in power of using l 00 > 0 over l 00 = 0 can be large. Figure S1 shows the average power and the power for at least one of our proposal as a function of c 2 ∈ {0.05, 0.1, . . . , 0.95} and l 00 ∈ {0, 0.5, 0.8, 0.9} for q = 0.05. As expected, both measures of power increase as l 00 increases. For fixed l 00 and (π 1 , π 2 ), the highest average power among all the choices of c 2 is close to the average power when c 2 = 0.5 ( Figure S1 , left column), also shown in Table S4 . The power curve for at least one as a function of c 2 is flat around c 2 = 0.5 ( Figure S1 , right column), suggesting as well that c 2 = 0.5 is an appropriate choice. Figure S2 shows the FDR of our proposal as a function of c 2 ∈ {0.05, 0.1, . . . , 0.95}, for l 00 ∈ {0, 0.5, 0.8, 0.9} and q = 0.05. It can be seen that the FDR is far below 0.05 for all the sets of parameters considered. This follows from the fact that our data generation may result in FDR much lower than the upper bound given in (1) . In order to see this, note that it follows from the proof of Theorem 1 that the FDR of our proposal achieves the upper bound in (1) when the p-values under the alternative are practically zero. In our simulation setting, this condition would hold if µ i , for i ∈ {1, 2} were always extremely large when compared to N(0, 1) random variables, e.g. µ i ≥ 4. Obviously this does not hold for our data generation process. Therefore we could get higher FDR values for another data generation process, however we still Table S4 : The estimated average power of our proposal with parameters (l 00 , c 2 , 0.05), where c 2 is the optimal choice among the values in {0.05, 0.1, . . . , 0.95} for l 00 = 0.5 (column 2), l 00 = 0.8 (column 4), l 00 = 0.9 (column 6), and l 00 = 0 (column 8), the optimal value of c 2 is given in the row below; c 2 = 0.5, for l 00 ∈ {0.5, 0.8, 0.9, 0} (columns 3, 5, 7, 9) in a configuration f 00 = 0.9, f 01 = f 10 = 0.025, f 11 = 0.05. The number of hypotheses examined in the primary study is 1000. The signal to noise ratios for the primary study and the follow-up study, µ 1 /σ 1 and µ 2 /σ 2 , respectively, are taken according to the requirement that the power of Bonferroni procedure at level 0.05 in the primary study is π 1 , and in the follow-up study is π 2 (given in the first column). The standard errors were of the order of 10 −3 or 10 −4 for all the estimates. would not expect to achieve 0.05 because of using conservative upper bounds for f 01 and E(|I 10 ∩ R 1 |/(max |R 1 |, 1)) in expression (1).
E GWAS simulation example
The goal of the simulation was threefold. First, to verify that the FDR is controlled below the nominal level for realistic simulations with GWAS type dependency, even if hypotheses with primary study p-values above c 1 (q)q/m are followed-up. Second, to compare the performance of our suggested proposal with the BH procedure on maximum p-values. Third, to examine the effect of l 00 on the power of the two procedures.
The information on l 00 is incorporated into the BH procedure on maximum p-values, to make the comparison fair, by performing the BH procedure at level q/(1 − l 00 ). It is straightforward to show that the FDR is controlled at level at most q for the BH procedure on the maximum p-values at level q/(1 − l 00 ), when the p-values within each study are independent.
We simulated two GWAS from the simulator HAPGEN2 [28] . The two studies were generated from two samples of the HapMap project [29] , a sample of 165 Utah residents with Northern and Western European ancestry (CEU), and a sample of 109 Chinese in Metropolitan Denver, Colorado (CHD). In the CEU and CHD populations, respectively, 34 and 38 SNPs were set as disease SNPs with an increased multiplicative relative risk of 1.2, and 18 of the disease SNPs were common to both populations. Each study contained 4500 cases and 4500 referents. The linkage disequilibrium (LD) Figure S1: The estimated average power (first column) and the probability of at least one true replicability claim (power for at least one, column 2) of our proposal with parameters (l 00 , c 2 , 0.05) as a function of c 2 in a simulation where f 00 = 0.9, f 01 = f 10 = 0.025, f 11 = 0.05, the number of hypotheses examined in the primary study is 1000, and the signal to noise ratios for the primary study and the follow-up study, respectively, are taken according to the requirement that the power of the Bonferroni procedure at level 0.05 in the primary study is π 1 , and in the follow-up study is π 2 for (π 1 , π 2 ) = (0.1, 0.2) (row 1), (π 1 , π 2 ) = (0.1, 0.5) (row 2), (π 1 , π 2 ) = (0.1, 0.8) (row 3); l 00 = 0.9 (solid), l 00 = 0.8 (dashed), l 00 = 0.5 (dash-dotted), and l 00 = 0 (dotted). The standard errors of the estimators were of the order of 10 −3 or 10 −4 for all the sets of parameters. Figure S2 : The estimated FDR of our proposal with parameters (l 00 , c 2 , 0.05) as a function of c 2 in a simulation where f 00 = 0.9, f 01 = f 10 = 0.025, f 11 = 0.05, the number of hypotheses examined in the primary study is 1000, and the signal to noise ratios for the primary study and the follow-up study, µ 1 /σ 1 and µ 2 /σ 2 , respectively, are taken according to the requirement that the power of the Bonferroni procedure at level 0.05 in the primary study is π 1 , and in the follow-up study is π 2 for (π 1 , π 2 ) = (0.1, 0.2) (left panel), (π 1 , π 2 ) = (0.1, 0.5) (middle panel), (π 1 , π 2 ) = (0.1, 0.8) (right panel); l 00 = 0.9 (solid), l 00 = 0.8 (dashed), l 00 = 0.5 (dash-dotted), and l 00 = 0 (dotted). The standard errors were of the order of 10 −3 or 10 −4 for all the sets of parameters.
across SNPs, as measured for the samples in the HapMap project, was retained. Due to LD, the number of SNPs associated with the phenotype in each study was larger than the number of disease SNPs. See [16] for the details of this simulation.
The CHD study was the primary study, and the CEU study was the follow-up study. SNPs were selected for follow-up only if they were discovered by the BH procedure at level c 1 (0.05) × 0.05. Table S5 presents the average number of replicated findings, as well as the average false discovery proportion (FDP), for our proposal with c 2 = 0.5 and q = 0.05, and the BH procedure on maximum p-values at level 0.05/(1 − l 00 ), for different values of l 00 . From columns 4 and 7 it is clear that the FDR is controlled and that our proposal is actually conservative, for all values of l 00 . From a comparison of columns 2 and 5 it is clear that our proposal is more powerful than the BH procedure on maximum p-values. Finally, from comparisons of the rows it is clear that the power increases as l 00 increases. Table S5 : For 4500 cases and 4500 referents in both studies, the average number of associated and disease SNPs discovered (SE), and the average FDP (SE), for different values of l 00 . The actual value of f 00 was above 0.999. Results are given for our proposal with c 2 = 0.05 and q = 0.05 in columns 2-4, and for the BH procedure on maximum p-values at level 0.05/(1 − l 00 ) in columns 5-7. SNPs were selected for follow-up only if they were discovered by the BH procedure at level c 1 (0.05) × 0.05. where the last inequality follows from the fact that P 1j is a null-hypothesis p-value. From summing over the upper bounds (22) , (24) , and (25) it thus follows that F W ER ≤ E(R 00 + R 10 + R 01 ) ≤ c 1 c 2 f 00 α 2 + f 01 c 1 α + c 2 αE |R 1 ∩ I 10 | max (|R 1 |, 1) .
